Medical therapy of Canine Cushing's syndrome

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 20, Issue 6, 1998, Pages 679-695

  Behrend, Ellen N ^a,b   Kemppainen, Robert J ^a  

^a AUBURN UNIVERSITY   (United States)

^b AMER COLL OF VET INT MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GYMNOMYZA SAMOENSIS;

EID: 3042902155     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Kemppainen RJ, Sartin JL: Differential regulation of peptide release by the canine pars distalis and pars intermedia. Front Horm Res 17:18-27, 1987.
2. Feldman EC, Nelson RW: Hyperadrenocorticism (Cushing's syndrome), in Canine and Feline Endocrinology and Reproduction, ed 2. Philadelphia, WB Saunders Co, 1996, pp 187-265.
3. Peterson ME, Krieger DT, Drucker WD: Immunocytochemical study of the hypophysis in 25 dogs with pituitary-dependent hyperadrenocorticism. Acta Endocrinol 101:15-24, 1982.
4. Capen CC, Martin SL, Koestner A: Neoplasms in the adenohypophysis of dogs. Pathol Vet 4:301-325, 1967.
5. Schechter RD, Stabenfeldt GH, Gribble DH, Ling GV: Treatment of Cushing's syndrome in the dog with an adrenocorticolytic agent (o,p'DDD). JAVMA 162:629-639, 1973.
6. Vilar O, Tullner WW: Effects of o,p'-DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex. Endocrinology 65:80-86, 1959.
7. Kirk GR, Boyer S, Hutcheson DP: Effects of o,p'-DDD on plasma cortisol levels and histology of the adrenal gland in the normal dog. JAAHA 10:179-182, 1974.
8. Watson ADJ, Rijnberk A, Moolenaar AJ: Systematic availability of o,p'-DDD in normal dogs, fasted and fed, and in dogs with hyperadrenocorticism. Res Vet Sci 43:160-165, 1987.
9. Kintzer PP, Peterson ME: Mitotane (o,p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 5:182-190, 1994.
10. Peterson ME, Kintzer PP: Medical treatment of pituitary-dependent hyperadrenocorticism. Vet Clin North Am Sm Anim Pract 27:255-272, 1997.
11. Peterson ME, Nesbitt GH, Schaer M: Diagnosis and management of concurrent diabetes mellitus and hyperadrenocorticism in 30 dogs. JAVMA 178:66-69, 1981.
12. Rijnberk A, Belshaw BE: o,p'DDD treatment of canine hyperadrenocorticism: An alternative protocol, in Kirk RW, Bonagura JD (eds): Current Veterinary Therapy XI: Small Animal Practice. Philadelphia, WB Saunders Co, 1992, pp 345-349.
13. Kintzer PP, Peterson ME: Treatment and long-term follow-up of 205 dogs with hypoadrenocorticism. J Vet Intern Med 11:43-49, 1997.
14. den Hertog E, Braakman JCA, Teske E: Treatment of pituitary-dependent hyperadrenocorticism in the dog by non-selective adrenocorticolysis with o,p'-DDD. Vet Quarterly 19:S17, 1997.
15. Kintzer PP, Peterson ME: Diagnosis and management of cortisol-secreting adrenal tumors. Vet Clin North Am Sm Anim Pract 27:299-307, 1997.
16. Feldman EC, Feldman MS, Farver TB: Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs. JAVMA 200:1642-1647, 1992.
17. Kintzer PP, Peterson ME: Mitotane treatment of 32 dogs with cortisol secreting adrenocortical neoplasms. JAVMA 225:54-61, 1994.
18. Rijnberk A, Voorhout G, Mol JA: Corticoid production by four dogs with hyperfunctioning adrenocortical tumors during treatment with mitotane (o,p'-DDD). Vet Rec 131:484-487, 1992.
19. Bruyette DS, Feldman EC: Ketoconazole and its use in the management of canine Cushing's disease. Compend Contin Educ Pract Vet 10:1379-1385, 1988.
20. Plumb DC: Veterinary Drag Handbook, ed 2. Ames, Iowa, Iowa State University Press, 1995.
21. Sonino N: The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 317:812-818, 1987.
22. DeCoster R, Beerens D, Dom J, Willemsens G: Endocrinological effects of single daily ketoconazole administration in male beagle dogs. Acta Endocrinol 107:275-281, 1984.
23. Loose DS, Kan PB, Hirst MA, et al: Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 71:1495-1499, 1983.
24. Loose DS, Stover EP, Feldman D: Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. J Clin Invest 72:404-408, 1983.
25. Willard MD, Nachreiner R, McDonald R, Roudebush P: Ketoconazole-induced changes in selected canine hormone concentrations. Am J Vet Res 47:2504-2509, 1986.
26. Feldman EC, Bruyette DS, Nelson RW, Farver TB: Plasma cortisol response to ketoconazole administration in dogs with hyperadrenocorticism. JAVMA 197:71-77, 1990.
27. Behrend EN, Clark TP, Kemppainen RJ: Efficacy of and side effects associated with use of ketoconazole as treatment of canine Cushing's syndrome (Abstr). J Vet Intern Med 10:182, 1996.
28. Feldman EC, Nelson RW: Use of ketoconazole for control of canine hyperadrenocorticism, in Kirk RW, Bonagura JD (eds): Current Veterinary Therapy XI: Small Animal Practice. Philadelphia, WB Saunders Co, 1992, pp 349-352.
29. Orth DN, Nicholson WC, Plue RE: Equine Cushing's disease: A variation on the human disease. Clin Res 28:884A, 1980.
30. Orth DN, Holscher MA, Wilson MG, et al: Equine Cushing's disease: Plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests. Endocrinology 110:1430-1441, 1982.
31. Love S: Equine Cushing's disease. Br Vet J 149:139-153, 1993.
32. Beech J: Treatment of hypophyseal adenomas. Compend Contin Educ Pract Vet 16:921-923, 1994.
33. Munoz MC, Dorfeste F, Ferrer O, et al: Pergolide treatment for Cushing's syndrome in a horse. Vet Rec 139:41-43, 1996.
34. Beck DJ: Effective long-term treatment of a suspected pituitary adenoma with bromocriptine mesylate in a pony. Equine Vet Educ 4:119-122, 1992.
35. Peterson ME, Palkovits M, Chiueh CC, et al: Biogenic amine and corticotropin-releasing factor concentrations in hypothalamic paraventricular nucleus and biogenic amine levels in the median eminence of normal dogs, chronic dexamethasone-treated dogs, and dogs with naturally-occurring pituitary-dependent hyperadrenocorticism (canine Cushing's disease). J Neuroendocrinol 1:169-171, 1989.
36. Zerbe CA, Clark TP, Sartin JL: Domperidone treatment enhances corticotropin-releasing hormone stimulated adrenocorticotropic hormone release from the dog pituitary. Neuroendocrinology 57:282-288, 1993.
37. Meijer JC, Croughs RJM, Rijnberk A, et al: Hypothalamic catecholamine levels in dogs with spontaneous hyperadrenocorticism. Neuroendocrinology 32:197-201, 1981.
38. Kooistra HS, Greven SH, Mol JA, Rijnberk A: Pulsatile secretion of CX-MSH and the differential effects of dexamethasone and haloperidol on the secretion of (X-MSH and ACTH in dogs. J Endocrinol 152:113-121, 1997.
39. Kemppainen RJ, Sartin JL: In vivo evidence for dopaminergic regulation of the canine pituitary intermediate lobe. Acta Endocrinol 113:441-478, 1986.
40. Mizobuchi M, Hineno T, Kakimoto Y, Hiratani K: Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated dogs. Brain Res 612:319-321, 1993.
41. Reid IA: Role of dopamine in the inhibition of vasopressin secretion by L-dopa in carbidopa-treated dogs. Hypertension 8:890-896, 1986.
42. Bruyette DS, Ruehl WW, Smidberg TL: Canine pituitary-dependent hyperadrenocorticism: A spontaneous animal model for neurodegenerative disorders and their treatment with 1-deprenyl. Prog Brain Res 106:207-213, 1995.
43. Kemppainen RJ, Zerbe CA, Sartin JL: Regulation and secretion of proopiomelanocortin peptides from isolated perifused dog pituitary pars intermedia cells. Endocrinology 124:2208-2217, 1989.
44. Drucker WD, Peterson ME: Pharmacologie treatment of pituitary-dependent canine Cushing's disease. Proc 62nd Annu Meet Endocr Soc: 89, 1980.
45. Rijnberk A, Mol JA, Kwant MM: Effects of bromocriptine on corticotrophin, melanotrophin, and corticosteroid secretion in dogs with pituitary-dependent hyperadrenocorticism. J Endocrinol 118:271-277, 1988.
46. Bruyette DS, Ruehl WW, Entriken T: Management of canine pituitary-dependent hyperadrenocorticism with 1-deprenyl (Anipryl®). Vet din North Am Sm Anim Pract 27:273-286, 1997.
47. Bruyette DS, Darling LA, Griffin D: L-deprenyl for canine pituitary-dependent hyperadrenocorticism: Pivotal clinical trials. J Vet Intern Med 10:182, 1996.
48. Steffen T, Horauf A, Reusch C: Selegiline-HCl (1-deprenyl) for treatment of canine pituitary-dependent hyperadrenocorticism. J Vet Intern Med 11:122, 1997.